Invenomic Capital Management LP Grows Stake in Integra LifeSciences Holdings Corporation $IART

Invenomic Capital Management LP raised its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 78.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,055,941 shares of the life sciences company’s stock after acquiring an additional 463,729 shares during the period. Invenomic Capital Management LP owned approximately 1.36% of Integra LifeSciences worth $13,115,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter worth $25,000. Osaic Holdings Inc. grew its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Integra LifeSciences by 145.9% in the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares in the last quarter. Finally, Amundi lifted its holdings in shares of Integra LifeSciences by 17,193.8% during the second quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 11,004 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Down 2.9%

Shares of NASDAQ:IART opened at $17.20 on Thursday. Integra LifeSciences Holdings Corporation has a 1 year low of $8.70 and a 1 year high of $18.19. The stock’s fifty day moving average price is $13.76 and its 200-day moving average price is $12.29. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The company has a market cap of $1.34 billion, a P/E ratio of -2.66, a PEG ratio of 1.23 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. During the same quarter in the prior year, the company earned $0.41 earnings per share. Integra LifeSciences’s revenue was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IART. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and upped their price target for the company from $11.00 to $16.00 in a report on Thursday, May 28th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Truist Financial lowered their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Wells Fargo & Company upped their price target on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $14.00.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.